Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus
Open Access
- 2 April 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 258 (7), 1207-1222
- https://doi.org/10.1007/s00415-011-5999-8
Abstract
We review current pharmacological treatments for peripheral and central vestibular disorders, and ocular motor disorders that impair vision, especially pathological nystagmus. The prerequisites for successful pharmacotherapy of vertigo, dizziness, and abnormal eye movements are the “4 D’s”: correct diagnosis, correct drug, appropriate dosage, and sufficient duration. There are seven groups of drugs (the “7 A’s”) that can be used: antiemetics; anti-inflammatory, anti-Ménière’s, and anti-migrainous medications; anti-depressants, anti-convulsants, and aminopyridines. A recovery from acute vestibular neuritis can be promoted by treatment with oral corticosteroids. Betahistine may reduce the frequency of attacks of Ménière’s disease. The aminopyridines constitute a novel treatment approach for downbeat and upbeat nystagmus, as well as episodic ataxia type 2 (EA 2); these drugs may restore normal “pacemaker” activity to the Purkinje cells that govern vestibular and cerebellar nuclei. A limited number of trials indicate that baclofen improves periodic alternating nystagmus, and that gabapentin and memantine improve acquired pendular and infantile (congenital) nystagmus. Preliminary reports suggest suppression of square-wave saccadic intrusions by memantine, and ocular flutter by beta-blockers. Thus, although progress has been made in the treatment of vestibular neuritis, some forms of pathological nystagmus, and EA 2, controlled, masked trials are still needed to evaluate treatments for many vestibular and ocular motor disorders, including betahistine for Ménière’s disease, oxcarbazepine for vestibular paroxysmia, or metoprolol for vestibular migraine.Keywords
This publication has 144 references indexed in Scilit:
- Muscimol inactivation caudal to the interstitial nucleus of Cajal induces hemi-seesaw nystagmusExperimental Brain Research, 2010
- The Therapeutic Mode of Action of 4-Aminopyridine in Cerebellar AtaxiaJournal of Neuroscience, 2010
- Crossover trial of gabapentin and memantine as treatment for acquired nystagmusAnnals of Neurology, 2010
- Oculopalatal tremor explained by a model of inferior olivary hypertrophy and cerebellar plasticityBrain, 2010
- Upbeat-Torsional Nystagmus and Contralateral Fourth-Nerve Palsy due to Unilateral Dorsal Ponto Mesencephalic LesionAnnals of the New York Academy of Sciences, 2009
- Treatment of Acquired Periodic Alternating Nystagmus With MemantineClinical Neuropharmacology, 2009
- The neuronal connexin36 interacts with and is phosphorylated by CaMKII in a way similar to CaMKII interaction with glutamate receptorsProceedings of the National Academy of Sciences, 2008
- Saccadic Burst Cell Membrane Dysfunction Is Responsible for Saccadic OscillationsJournal of Neuro-Ophthalmology, 2008
- Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmusNature Genetics, 2006
- Vertical nystagmus: clinical facts and hypothesesBrain, 2005